Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on Oct 16, 2024 3:20pm
161 Views
Post# 36268674

Updated Presentation

Updated Presentation Interesting slide (page 17) gives details around the proposed Phase II/III mBC trial.

ONCY has stated that trial will begin Q2 2025, and from the slide they would be able to apply for Accelerated Approval with 109 patient's worth of data. the slide suggests that this data would be available after 18 months. Failing the desired outcome, the trial would ensue to measuring OS.(123 events).

So... Inflection Points to come...

1) Partner to pay for this trial..? ONCY needs not just operating capital (it'll need a year's worth soon + money for the trial if going it alone). So partner = salvation, no partner = massive dilution, and ongoing dilution until 2028. 
2) First patient treated (I wonder if this will still trigger milestone payments from Adlai Nortye?)
3) Data allows for submission of AA
4) Approval

Best one can hope for is accelerated approval by Q1/Q2 2028. Only 25 years after Brad Thomson's prediction of 2003... cool
<< Previous
Bullboard Posts
Next >>